openPR Logo
Press release

New Research Report on Kinase Inhibitors For Cancer Treatment, 2016-2026

09-01-2016 08:27 AM CET | Health & Medicine

Press release from: Future Market Insights

New Research Report on Kinase Inhibitors For Cancer Treatment,

Kinase Inhibitors are specific enzymes which oppose the process of cell division and growth in cancerous cells. It comes handy in treatment of cancer by blocking the signals that notify a cell to divide and grow. In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy. However, these drugs used cancer treatment have a restricted therapeutic index, also the result are only unpredictable, partial, brief, palliative as well as uncertain. In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways. Such targets are normally found in tumor cells, resulting wider therapeutic index and minimum adverse effect.

Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth. This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years. Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.

Kinase Inhibitors for Cancer Treatment Market: Drivers and Restraints

Enhancedemphasis of pharmaceutical companies on R&D to come up with potential kinase inhibitors for treatment of cancers. Is driving the growth of kinase inhibitor treatment market, globally. Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease. However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1403

Kinase Inhibitors for Cancer Treatment Market: Segmentation

Kinase inhibitors for cancer treatment globalmarketis segmented into following types:

By Product Type

Angiogenesis inhibitors

m-TOR inhibitors

BRAF and MEK inhibitors

Bcr-Abl tyrosine-kinase inhibitors (TKI)

EGFR inhibitors

Others (PI3K Inhibitors, aurora-kinase inhibitors etc)

End User

Hospitals

Research Organizations

By Region

North America

Latin America

Western Europe

Eastern Europe

APEJ

Japan

MEA

Kinase Inhibitors for Cancer Treatment Market: Overview

The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period. There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.

Kinase Inhibitors for Cancer Treatment Market: Region-wise Outlook

Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients. Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1403

Kinase Inhibitors for Cancer Treatment Market: Key Players

Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Research Report on Kinase Inhibitors For Cancer Treatment, 2016-2026 here

News-ID: 359904 • Views:

More Releases from Future Market Insights

Maca Magic Unleashed: Black Maca Extract Market Set to Hit USD 119.1 million by 2035 as Innovation Powers Wellness Boom
Maca Magic Unleashed: Black Maca Extract Market Set to Hit USD 119.1 million by …
The Quiet Revolution of Natural Wellness: Market Trajectory The global market for Black Maca Extract is experiencing a powerful, yet consistent, surge driven by the modern consumer's pivot toward natural and proactive health management. Far from a passing fad, this market is demonstrating robust and stable growth, with projections showing its value will nearly double over the next decade. Based on recent analysis, the market is set to expand from an
Fluoroquinolones ELISA Kit Market to Reach USD 144.7 Million by 2035 with 8.5% CAGR Growth
Fluoroquinolones ELISA Kit Market to Reach USD 144.7 Million by 2035 with 8.5% C …
The global fluoroquinolones ELISA kit market is set to undergo a decade of steady and transformative growth, rising from an estimated USD 64 million in 2025 to a projected USD 144.7 million by 2035. This expansion, at a compound annual growth rate (CAGR) of 8.5%, reflects the increasing need for accurate, reliable, and efficient diagnostic tools across industries such as food safety, pharmaceuticals, veterinary care, and environmental monitoring. From 2021 to
Medical Implants Precision Machining Service Market Poised for 6.4% CAGR Growth to 2035
Medical Implants Precision Machining Service Market Poised for 6.4% CAGR Growth …
Global Market Outlook: A Decade of Expanding Precision The medical implants precision machining service market is entering a decisive decade, with a strong growth trajectory driven by demand for advanced surgical solutions and innovations in multi-axis machining technologies. According to new projections, the market will expand from USD 1,056.4 million in 2025 to USD 1,964.5 million by 2035, marking a compound annual growth rate (CAGR) of 6.4%. Between 2021 and 2025, the
NGS Solution for Early Cancer Screening Market to Reach USD 2,393.5 million by 2035 Amid Precision Medicine Growth
NGS Solution for Early Cancer Screening Market to Reach USD 2,393.5 million by 2 …
Early Cancer Detection Enters a Transformative Era The fight against cancer is undergoing a profound transformation as the global healthcare sector accelerates the adoption of next-generation sequencing (NGS) technologies for early cancer detection. According to market forecasts, the NGS solution for early cancer screening market will grow from USD 591.6 million in 2025 to nearly USD 2,393.5 million by 2035, representing a 305% total growth and a 15% compound annual growth

All 5 Releases


More Releases for Kinase

Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors 2. Tyrosine Kinase: An Overview 3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies 4. Types of Tyrosine Kinase Receptors 4.1 Epidermal Growth Factor Receptor 4.1.1 Types of Epidermal Growth Factor Receptor 4.1.2 Epidermal Growth Factor Receptor & Ligands 4.1.3
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Bet …
According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157712 Mitogen Activated Protein Kinase Kinase Kinase 7
Tyrosine Protein Kinase JAK3 (Janus Kinase 2 or JAK3 or EC 2.7.10.2) – Pharmac …
Market Research Hub report titled ‘Tyrosine Protein Kinase JAK3 Pipeline’ (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline …
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with
Orbis Research - Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Cataly …
Description: Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 9
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stres …
Market Reports Center’s, ‘Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016’, provides in depth analysis on Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c